|
prime sponsor
|
Keynote Speaker: Jim Tullis - Founder and CEO of Tullis-Dickerson & Co., Inc.
|
|
Keynote Address by Jim Tullis
- Rational Exuberance -
Life Sciences. Medical Technology. Healthcare.
“A New Perspective for the Venture Capital Investor”
Background & Overview
In 2003, U. S. venture capital investments totaled $18.2 billion in 2,715 companies, a decline of 15 percent from the previous year. Life sciences, including biotechnology and medical devices together, attracted $4.89 billion or 27 percent of all venture capital - the highest proportion directed to life sciences in the last 12 years. According to the Price Waterhouse/Thomson Financial - Money Tree survey, biotechnology received $1.1 billion of total investments in fourth quarter 2003 and was the leading industry category for the second consecutive quarter, outpacing software, which accounted for $978 million in the quarter. As a result of the continued dominance of life sciences and medical technology as venture capital’s investments of choice, our keynote speaker will be Jim Tullis, the founder and CEO of Tullis-Dickerson & Co., a leading venture capital firm that has invested almost exclusively in healthcare since inception. Jim will focus on the reasons behind this growing trend and what the future holds for VC investments in life sciences. Conference attendees will also learn which sectors are likely to produce the most profit as well as what consumer trend and demands will have the greatest effect on healthcare investments.
Keynote Speaker - Jim Tullis
Jim Tullis is the Founder and Chief Executive Officer of Tullis-Dickerson & Co., Inc. Prior to establishing Tullis-Dickerson, Mr. Tullis had a distinguished career on Wall Street. At Morgan Stanley, he led healthcare investment research, focusing on pharmaceuticals and medical devices. He was listed 14 times on the Institutional Investor All-Star list of Wall Street's top securities analysts, was twice named #1 Drug Analyst, and was featured on the Wall Street Week television program. He wrote Wall Street's first research report on biotechnology. Under his direction, Tullis-Dickerson has invested in a portfolio of companies representing innovative concepts in pharmaceuticals, biotechnology, health insurance, healthcare information technology, medical distribution, and medical devices. Mr. Tullis is currently on the Board of several public and private companies. Mr. Tullis is a graduate of Stanford University and earned an MBA from Harvard Business School.
About Tullis-Dickerson & Co.
Tullis-Dickerson & Co. is one of the country’s largest health care-focused private equity groups, providing capital to small and mid-sized companies. The firm provides seed through late stage capital to creative, committed management teams leading growth companies.
Through its established national and regional presence, Tullis-Dickerson has provided leadership, guidance and capital to a broad group of successful businesses, which have in some cases surpassed the billion-dollar revenue level and operate on a global basis.
|
|
